http://weekly.chinacdc.cn/ China CDC Weekly cdcwjournal@163.com cdcwjournal@163.com en cdcwjournal@163.com 2096-7071 http://weekly.chinacdc.cn/article/doi/10.46234/ccdcw2020.156?pageType=en Shicheng Yu, Qiqi Wang, Shujun Wang, Jiaojiao Zhang, Yuehua Hu, Junqi Li, Xiaojuan Long, Xianglong Xiang, Maigeng Zhou, Feng Tan <sec<<p< <b<What is already known about this topic?</b< </p<</sec<<sec<<p<The World Health Organization’s (WHO) Global Health Estimates (GHE) reported that acute hepatitis caused 9,213 deaths and 307,720 person years of disability-adjusted life years (DALYs) in 2016, and acute hepatitis B accounted for 85.81% of all DALYs among acute hepatitis types A, B, C, and E in China.</p<</sec<<sec<<p< <b<What is added by this report?</b< </p<</sec<<sec<<p<In China, the percent changes in years lived with disability (YLDs) due to acute hepatitis A, B, and E in groups aged 50–69 years and 70 years or more and in all age groups for acute hepatitis C were increased from 2000 to 2019.</p< </sec<<sec<<p< <b<What are the implications for public health practices?</b< </p<</sec<<sec<<p<Effective vaccines, interventions, and treatments are key approaches to achieve the WHO’s goal of reducing new hepatitis infections by 90% and deaths by 65% between 2016 and 2030.</p<</sec< China CDC Weekly. 2020 2(31): 579-586. Shicheng Yu, Qiqi Wang, Shujun Wang, Jiaojiao Zhang, Yuehua Hu, Junqi Li, Xiaojuan Long, Xianglong Xiang, Maigeng Zhou, Feng Tan <sec<<p< <b<What is already known about this topic?</b< </p<</sec<<sec<<p<The World Health Organization’s (WHO) Global Health Estimates (GHE) reported that acute hepatitis caused 9,213 deaths and 307,720 person years of disability-adjusted life years (DALYs) in 2016, and acute hepatitis B accounted for 85.81% of all DALYs among acute hepatitis types A, B, C, and E in China.</p<</sec<<sec<<p< <b<What is added by this report?</b< </p<</sec<<sec<<p<In China, the percent changes in years lived with disability (YLDs) due to acute hepatitis A, B, and E in groups aged 50–69 years and 70 years or more and in all age groups for acute hepatitis C were increased from 2000 to 2019.</p< </sec<<sec<<p< <b<What are the implications for public health practices?</b< </p<</sec<<sec<<p<Effective vaccines, interventions, and treatments are key approaches to achieve the WHO’s goal of reducing new hepatitis infections by 90% and deaths by 65% between 2016 and 2030.</p<</sec< China CDC Weekly. 2020 2(31): 579-586. Burden of Acute Viral Hepatitis — China, 1990−2019 Shicheng Yu, Qiqi Wang, Shujun Wang, Jiaojiao Zhang, Yuehua Hu, Junqi Li, Xiaojuan Long, Xianglong Xiang, Maigeng Zhou, Feng Tan 2020-07-31 Personal use only, all commercial or other reuse prohibited China CDC Weekly. 2020 2(31): 579-586. article doi:10.46234/ccdcw2020.156 10.46234/ccdcw2020.156 China CDC Weekly 2 31 2020-07-31 http://weekly.chinacdc.cn/article/doi/10.46234/ccdcw2020.156?pageType=en 579 http://weekly.chinacdc.cn/article/doi/10.46234/ccdcw2020.157?pageType=en Faxin Hei, Guowei Ding, Shaodong Ye, Hailiang Yu, Lin Pang, Zhongfu Liu <sec< <p< <b<What is already known on this topic?</b< </p<</sec<<sec< <p<To understand the status of the diagnosis and reporting of hepatitis C and standardize the reporting of hepatitis C cases in county-level hospitals, we conducted the first supervised analysis of hepatitis C cases in county-level hospitals in China from 2013 to 2018, covering all provincial-level administrative divisions (PLADs) except Tibet.</p<</sec<<sec< <p< <b<What is added by this report?</b< </p<</sec<<sec< <p<Through 6 years of supervision, we have obtained key data such as the nucleic acid detection rate and positive rate of hepatitis C virus (HCV) antibody positive cases in our county-level hospitals, the report rate and accuracy of HCV RNA positive cases, and standardized and improved the hepatitis C case reporting in county-level hospitals to improve data quality and provide data support for the judgment and estimation of hepatitis C in China.</p<</sec<<sec< <p< <b<What are the implications for public health practice?</b< </p<</sec<<sec< <p<By strengthening the management and supervision of hepatitis C case reporting, the reporting rate and accuracy of HCV RNA positive cases in county-level hospitals in China had been greatly improved. By combining the number of HCV antibody tests and the number of viral nucleic acid tests in medical institutions around the country, it was possible to effectively assess the current status of hepatitis C in China and to provide a scientific basis for the development of hepatitis C prevention and treatment measures.</p<</sec< China CDC Weekly. 2020 2(31): 587-590. Faxin Hei, Guowei Ding, Shaodong Ye, Hailiang Yu, Lin Pang, Zhongfu Liu <sec< <p< <b<What is already known on this topic?</b< </p<</sec<<sec< <p<To understand the status of the diagnosis and reporting of hepatitis C and standardize the reporting of hepatitis C cases in county-level hospitals, we conducted the first supervised analysis of hepatitis C cases in county-level hospitals in China from 2013 to 2018, covering all provincial-level administrative divisions (PLADs) except Tibet.</p<</sec<<sec< <p< <b<What is added by this report?</b< </p<</sec<<sec< <p<Through 6 years of supervision, we have obtained key data such as the nucleic acid detection rate and positive rate of hepatitis C virus (HCV) antibody positive cases in our county-level hospitals, the report rate and accuracy of HCV RNA positive cases, and standardized and improved the hepatitis C case reporting in county-level hospitals to improve data quality and provide data support for the judgment and estimation of hepatitis C in China.</p<</sec<<sec< <p< <b<What are the implications for public health practice?</b< </p<</sec<<sec< <p<By strengthening the management and supervision of hepatitis C case reporting, the reporting rate and accuracy of HCV RNA positive cases in county-level hospitals in China had been greatly improved. By combining the number of HCV antibody tests and the number of viral nucleic acid tests in medical institutions around the country, it was possible to effectively assess the current status of hepatitis C in China and to provide a scientific basis for the development of hepatitis C prevention and treatment measures.</p<</sec< China CDC Weekly. 2020 2(31): 587-590. Supervised Analysis of Hepatitis C Virus RNA-Positive Case Reporting in County-Level Hospitals — China, 2013−2018 Faxin Hei, Guowei Ding, Shaodong Ye, Hailiang Yu, Lin Pang, Zhongfu Liu 2020-07-31 Personal use only, all commercial or other reuse prohibited China CDC Weekly. 2020 2(31): 587-590. article doi:10.46234/ccdcw2020.157 10.46234/ccdcw2020.157 China CDC Weekly 2 31 2020-07-31 http://weekly.chinacdc.cn/article/doi/10.46234/ccdcw2020.157?pageType=en 587 http://weekly.chinacdc.cn/article/doi/10.46234/ccdcw2020.158?pageType=en Xiaojin Sun, Fuzhen Wang, Guomin Zhang, Hui Zheng, Ning Miao, Zundong Yin, Zhijie An China CDC Weekly. 2020 2(31): 591-595. Xiaojin Sun, Fuzhen Wang, Guomin Zhang, Hui Zheng, Ning Miao, Zundong Yin, Zhijie An China CDC Weekly. 2020 2(31): 591-595. Progress Towards Hepatitis A Control and Prevention Through 2019: the National Immunization Program of China Xiaojin Sun, Fuzhen Wang, Guomin Zhang, Hui Zheng, Ning Miao, Zundong Yin, Zhijie An 2020-07-31 Personal use only, all commercial or other reuse prohibited China CDC Weekly. 2020 2(31): 591-595. article doi:10.46234/ccdcw2020.158 10.46234/ccdcw2020.158 China CDC Weekly 2 31 2020-07-31 http://weekly.chinacdc.cn/article/doi/10.46234/ccdcw2020.158?pageType=en 591 http://weekly.chinacdc.cn/article/doi/10.46234/ccdcw2020.159?pageType=en Yu Wang, Min Wang, Guanhua Zhang, Xiaojuan Ou, Hong Ma, Hong You, Jidong Jia China CDC Weekly. 2020 2(31): 596-600. Yu Wang, Min Wang, Guanhua Zhang, Xiaojuan Ou, Hong Ma, Hong You, Jidong Jia China CDC Weekly. 2020 2(31): 596-600. Control of Chronic Hepatitis B in China: Perspective of Diagnosis and Treatment Yu Wang, Min Wang, Guanhua Zhang, Xiaojuan Ou, Hong Ma, Hong You, Jidong Jia 2020-07-31 Personal use only, all commercial or other reuse prohibited China CDC Weekly. 2020 2(31): 596-600. article doi:10.46234/ccdcw2020.159 10.46234/ccdcw2020.159 China CDC Weekly 2 31 2020-07-31 http://weekly.chinacdc.cn/article/doi/10.46234/ccdcw2020.159?pageType=en 596 http://weekly.chinacdc.cn/article/doi/10.46234/ccdcw2020.160?pageType=en Peter Hao, Yu Chen, Zhenjun Li, Jingjing Xi, Feng Tan China CDC Weekly. 2020 2(31): 601-602. Peter Hao, Yu Chen, Zhenjun Li, Jingjing Xi, Feng Tan China CDC Weekly. 2020 2(31): 601-602. Qiyong Liu, China CDC’s Chief Expert of Vector Control Peter Hao, Yu Chen, Zhenjun Li, Jingjing Xi, Feng Tan 2020-07-31 Personal use only, all commercial or other reuse prohibited China CDC Weekly. 2020 2(31): 601-602. article doi:10.46234/ccdcw2020.160 10.46234/ccdcw2020.160 China CDC Weekly 2 31 2020-07-31 http://weekly.chinacdc.cn/article/doi/10.46234/ccdcw2020.160?pageType=en 601 http://weekly.chinacdc.cn/article/doi/10.46234/ccdcw2020.161?pageType=en China CDC Weekly. 2020 2(31): 603-604. China CDC Weekly. 2020 2(31): 603-604. Reported Cases and Deaths of National Notifiable Infectious Diseases — China, June, 2020 2020-07-31 Personal use only, all commercial or other reuse prohibited China CDC Weekly. 2020 2(31): 603-604. article doi:10.46234/ccdcw2020.161 10.46234/ccdcw2020.161 China CDC Weekly 2 31 2020-07-31 http://weekly.chinacdc.cn/article/doi/10.46234/ccdcw2020.161?pageType=en 603

map